Dear Colleagues,

 

The tricuspid valve is progressively gaining importance thanks to the new evidences which corroborates the prognostic importance of both organic and functional tricuspid regurgitation (FTR). In particular, if left untreated, FTR is not a simple bystander but contributes to the progressive deterioration of right ventricular function and to the systemic congestion syndrome which characterizes this valvulopathy. Surgery represents the gold standard for the correction of both functional and organic TR, however surgical repair/replacement of tricuspid valve is limited by a high morbidity and mortality rate. In this setting, new percutaneous treatments are under development to address this unmet clinical need. This special issue will give a comprensive overview of the problem focusing on the clinical aspects related to tricuspid valve disease as well as on the surgical and percutaneous treatments that are currently available and that will be developed in the near future. 

 

Dr. Antonio Mangieri and Azeem Latib

Guest Editor